Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatments for central nervous system disease based on human neural stem cells and the use of small molecule compounds. The company?s stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical program products include NSI?566, which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, and Phase I clinical trials for chronic spinal cord injury. The company?s clinical development products also comprise NSI?566 that is in Phase I/II clinical trials for motor deficits due to ischemic stroke in China; and NSI?189 that is in Phase Ib for the treatment of major depressive disorders. Neuralstem, Inc. was founded in 1996 and is headquartered in Rockville, Maryland.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-40%||Sales Growth - Q/Q||-40%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-70.66%||ROE||-112.4%||ROI||-82.24%|
|Current Ratio||6.72||Quick Ratio||Long Term Debt/Equity||0.28||Debt Ratio||0.22|
|Gross Margin||Operating Margin||-93733.3%||Net Profit Margin||-120900%||Dividend Payout Ratio|
|Cash From Financing Activities||5.89 M||Cash From Investing Activities||-100 K||Cash From Operating Activities||-4.72 M||Gross Profit|
|Net Profit||-5.05 M||Operating Profit||-4.61 M||Total Assets||30.8 M||Total Current Assets||29.15 M|
|Total Current Liabilities||4.34 M||Total Debt||8.88 M||Total Liabilities||11.44 M||Total Revenue|
|High 52 week||1.8||Low 52 week||0.3||Last close||0.51||Last change||5.99%|
|RSI||59.01||Average true range||0.07||Beta||0.73||Volume||457.73 K|
|Simple moving average 20 days||11.62%||Simple moving average 50 days||3.16%||Simple moving average 200 days||-28.14%|
|Performance Week||-4.74%||Performance Month||13.13%||Performance Quart||33.33%||Performance Half||-32.27%|
|Performance Year||-68.71%||Performance Year-to-date||62.89%||Volatility daily||7.48%||Volatility weekly||16.72%|
|Volatility monthly||34.28%||Volatility yearly||118.73%||Relative Volume||618.32%||Average Volume||248.04 K|
|New High||New Low|
2019-06-03 14:55:22 | Germantown biopharma stock on the brink of delisting
2019-05-14 16:30:00 | Neuralstem Reports First Quarter 2019 Fiscal Results
2019-05-06 07:00:00 | Neuralstem Appoints David J. Mazzo, Ph.D., to Board of Directors
2019-04-29 10:02:41 | Some Neuralstem NASDAQ:CUR Shareholders Have Copped A 99% Share Price Wipe Out
2019-03-22 16:30:00 | Neuralstem Reports Year End 2018 Fiscal Results
2019-02-07 07:00:00 | Neuralstem to Expand Pipeline as Part of Aggressive Growth Effort
2018-12-18 07:00:00 | Neuralstem Appoints Ken Carter, Ph.D., as Executive Chairman of the Board
2018-12-04 05:00:00 | Germantown biotech faces stock delisting threat
2018-11-27 10:22:20 | How Financially Strong Is Neuralstem Inc NASDAQ:CUR?
2018-11-19 07:55:00 | Market Trends Toward New Normal in Neuralstem, Industrial Services of America, Gulf Resources, Natural Alternatives International, Lifevantage, and Lonestar Resources US — Emerging Consolidated Expectations, Analyst Ratings
2018-11-14 17:00:00 | Neuralstem Reports Third Quarter 2018 Financial Results and Provides Business Update
2018-10-26 09:00:00 | Neuralstem Announces $2.1 Million Registered Direct Offering
2018-09-18 11:20:37 | Should You Have Neuralstem Inc’s NASDAQ:CUR In Your Portfolio?
2018-08-15 10:24:24 | Neuralstem Provides Business Update and Reports Second Quarter 2018 Fiscal Results
2018-08-07 14:41:23 | Germantown biopharma Neuralstem appoints interim CEO
2018-08-06 07:00:00 | Neuralstem Appoints Jim Scully as Interim Chief Executive Officer
2018-08-01 09:05:46 | CORRECTING and REPLACING -- Neuralstem, Inc.
2018-07-31 18:14:42 | Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-189 in Ischemic Stroke
2018-05-29 07:00:00 | Neuralstem to Participate at the BIO 2018 International Convention
2018-05-15 07:00:00 | Neuralstem Provides Business Update and Reports First Quarter 2018 Fiscal Results
2018-04-11 08:30:00 | Today’s Research Reports on Trending Tickers: Neuralstem and Immunomedics
2018-04-02 07:30:00 | Neuralstem Reports Year End 2017 Fiscal Results and Business Update
2018-03-12 07:00:00 | Neuralstem to Participate at Upcoming Investor Conferences
2018-02-08 07:00:00 | Neuralstem to Participate at The Young Jewish Professionals CEO Healthcare Symposium
2018-01-22 07:00:00 | Neuralstem to Participate at Cell and Gene Therapy World
2017-12-26 11:25:27 | ETFs with exposure to Neuralstem, Inc. : December 26, 2017
2017-12-20 07:30:00 | New Member appointed to the Board of Directors of Neuralstem
2017-12-08 08:20:00 | Today’s Research Reports on Trending Tickers: Geron Corporation and Neuralstem, Inc.
2017-12-07 13:26:54 | ETFs with exposure to Neuralstem, Inc. : December 7, 2017
2017-12-06 08:00:00 | Today’s Research Reports on Stocks to Watch: Neuralstem, Inc. and Biocept Inc.
2017-12-06 07:53:00 | 800%+ Revenue Growth Could Imply 200-300% Returns for This Small Cap Stock
2017-11-30 11:45:08 | Does Neuralstem Inc’s CUR Past Performance Indicate A Stronger Future?
2017-11-13 07:41:27 | Neuralstem reports 3Q loss